RadNet, Inc. (RDNT) Stock: Price, Forecast & Analyst Target
RadNet, Inc. (RDNT) — MoonshotScore 33/100 (Weak band), calculated Oct 4, 2026. Price $69.93 (+3.29%), as of the Oct 2, 2026 trading session; market cap $5.50B.
Educational signal · not a buy or sell recommendation · How to read this
RadNet, Inc. · RDNT · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-13: RadNet operates a network of outpatient diagnostic imaging centers across the United States, offering MRI, CT, PET, mammography, and other advanced imaging services. The key question for investors is whether RadNet can grow volumes and pricing power in a market where consolidation is accelerating and payment rates are compressing.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · RadNet (RDNT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — a fragile balance sheet underneath; a move to treat with suspicion, not chase. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Flat; Momentum: Rising.
- quarterly revenue $623M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 1.84 · Piotroski F 4
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 33 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 33 | Weak | |
| 33 | Weak |
The score was 33 in the stored Oct 3, 2026 snapshot and remains 33 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $69.93 | |
| Change on the day | +3.29% | |
| 52-week range | $50.82–$85.84 | |
| Market capitalisation | $5.50B | |
| Shares traded on the day | 574.2K | |
| Beta (volatility vs the S&P 500) | 1.4 |
Price & events
Point at or tab to any week for its close.
Council Score · weighted blend of 2 available disciplines
Council score for RadNet (RDNT): Split View
37/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the RDNT film — every key number, told as a short cinematic story
~2 min · open the film
What is RadNet (RDNT), and what does it report?
Short answer · as of
RadNet is a healthcare services operator—not a medical device maker, not a staffing agency. Revenue comes from imaging procedures performed at owned or managed centers.
Research dated 2026-09-13.
RadNet is a healthcare services operator—not a medical device maker, not a staffing agency. Revenue comes from imaging procedures performed at owned or managed centers. What drives the numbers is patient volume, average revenue per procedure, and labor costs relative to revenue.
What do the latest results show for RadNet (RDNT)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $623M.
Research dated 2026-09-13.
Revenue grew in the latest quarter compared to the prior-year period, and the company swung to a small profit after losses in the preceding quarter. The turnaround suggests either better operating discipline, higher patient volume, or favorable mix shift toward higher-margin procedures.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $623M | $8M | $0.10 (diluted) |
| Q1 FY2026 | $576M | -$33M | -$0.43 (diluted) |
| Q4 FY2025 | $548M | -$597,000 | -$0.01 (diluted) |
| Q3 FY2025 | $523M | $5M | $0.07 (diluted) |
What are the financial strengths and risks for RadNet (RDNT)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The balance sheet carries substantial debt relative to equity and market value. Operating cash flow is positive despite negative net income in prior quarters, a sign that the company generates cash but has high capital requirements. The principal risk is payment rate compression from insurance companies and shifts in payer mix toward lower-paying programs.
Data-derived red flags
- Negative return on equity (-1.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
What should you watch next at RadNet (RDNT)?
Short answer · as of
Current published price targets run low $65.00 · high $65.00 · consensus $65.00 · median $65.00 against a quoted price of $69.93 (as of Oct 2, 2026).
Research dated 2026-09-13.
Upcoming reports should show whether procedure volumes are sustaining in the face of economic weakness and whether the company is gaining or losing market share in key metro areas. Watch for commentary on reimbursement rates and payer mix, as commercial insurance reimbursement exceeds government program rates significantly.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does RadNet compare with its peers?
Short answer
RadNet's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
RadNet differs from hospital-based imaging by focusing on outpatient centers, which have lower overhead and faster patient throughput. However, hospital consolidation is reducing the universe of independent centers RadNet can acquire at reasonable prices.
| Company | Price | Market value | Score |
|---|---|---|---|
| $322.28 Oct 2, 2026 | $9.54B | 97 5-pillar Oct 4, 2026 | |
| $105.90 Oct 2, 2026 | $4.87B | 96 5-pillar Oct 4, 2026 | |
| $67.15 Oct 2, 2026 | $3.47B | 94 5-pillar Oct 4, 2026 | |
| $599.47 Oct 2, 2026 | $16.7B | 92 5-pillar Oct 4, 2026 | |
| $507.50 Oct 2, 2026 | $6.63B | 87 5-pillar Oct 4, 2026 | |
| $44.75 Oct 2, 2026 | $9.23B | 87 5-pillar Oct 4, 2026 | |
| $60.25 Oct 2, 2026 | $11.8B | 83 5-pillar Oct 4, 2026 | |
| $18.22 Oct 2, 2026 | $5.20B | 77 5-pillar Oct 4, 2026 | |
| $162.05 Oct 2, 2026 | $12.4B | 70 5-pillar Oct 4, 2026 | |
| $290.19 Oct 2, 2026 | $14.0B | 62 5-pillar Oct 4, 2026 | |
| $63.24 Oct 2, 2026 | $9.63B | 59 5-pillar Oct 4, 2026 | |
| $188.67 Oct 2, 2026 | $11.8B | 36 5-pillar Oct 4, 2026 | |
| RadNet (RDNT) — this page | $69.93 | $5.50B | 33 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $65.00 – $65.00
- Consensus target
- $65.00
- Median target
- $65.00
Consensus record · Captured .
Measured against a quoted price of $69.93 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jun 18, 2026
- Transactions
- 11
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 4
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about RadNet (RDNT)?
Common Questions About RDNT (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is RadNet's primary source of revenue?
RadNet owns and operates outpatient imaging centers that perform MRI, CT, PET, mammography, and other diagnostic procedures. Revenue comes from per-procedure fees paid by insurance companies and self-pay patients.
Why would an investor prefer RadNet to hospital stocks?
RadNet operates purely on outpatient imaging with lower overhead than hospital-integrated centers. Profitability is more sensitive to payer rates and volume, but margins are typically higher than hospital radiology departments.
How concentrated is RadNet's revenue among major insurers?
RadNet contracts with multiple payers across commercial, Medicare, and Medicaid. Concentration risk exists with large regional or regional insurers, but no single customer appears to dominate revenue.
What would recession do to imaging procedure demand?
Elective procedures would likely decline as patients defer non-urgent care. Urgent diagnostic imaging would remain steady. The revenue hit would be significant unless RadNet offsets it with price increases or achieves better payer mix.
What is the RDNT stock price today?
The last price recorded on this page for RadNet, Inc. (RDNT) is $69.93, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RDNT price target?
The analyst consensus price target for RadNet, Inc. (RDNT) is $65.00 (range $65.00 to $65.00, median $65.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (27 figures)
The 27 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | LOS Angeles, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1508, 1510 and 1516 Cotner Avenue, Los Angeles, CA, 90025, US". |
FMP — 21 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $69.93 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T17:04:30.334Z. | |
px.change | Change on the day | +3.29% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $5.50B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-04. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$2.23 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $623M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $50.82–$85.84 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 574.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 1.4 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Howard G. Berger | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 9,060 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY1970 through FY2025: FY1970 revenue $0.00, net result $0.00; FY2022 revenue $0.00, net result $0.00; FY2023 revenue $0.00, net result $0.00; FY2024 revenue $0.00, net result $0.00; FY2025 revenue $0.00, net result $0.00 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 17.3% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. The market-value ratio is undefined when the reported amount is zero. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 5.02× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
earn.pt | Stored analyst price targets | low $65.00 · high $65.00 · consensus $65.00 · median $65.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $65.00 – $65.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $65.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $65.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 11 transactions · 0 purchases, 4 sales, 7 other transactions · 7 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jun 18, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-17 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 1.84 · Piotroski F 4 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -1.4% · ROA -0.4% · current ratio 1.17 · earnings yield -0.3% · free-cash-flow yield -3.2% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 33 of 100 · Weak · pillars 61 / 12 / 55 / 50 / 73 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 33 (stored snapshot Oct 3, 2026) → 33 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research The company's SEC filings classify it under SIC 8071 — Services-Medical Laboratories. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Employees | Count: 9,060 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing |
| Revenue by segment | Medicaid1: $51.74M; Medicare1: $476.99M; Health Care, Other: $65.02M; Commercial Insurance1: $1.13B; Capitation Arrangements: $125.54M | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| SEC filing business address | 1510 COTNER AVE, LOS ANGELES, CA, 90025 The SEC filer business address. Our market-data provider separately lists "1508, 1510 and 1516 Cotner Avenue, Los Angeles, CA, 90025, US". | 2026-09-13 | OFFICIAL | SEC EDGAR filer business address |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Trailing twelve-month ratio set | Quick ratio: 1.48; Current ratio: 1.48; Debt to equity: 1.99; Net margin: -0.9%; Gross margin: 9.7%; Operating margin: 4%; Return on assets: -0.5%; Return on equity: -2% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Cash, investments and debt | Total debt: $2.18B; Liquidity basis: cash and short-term investments; Total liabilities: $2.83B; Cash and short-term investments: $726.27M; Cash and investments: $861.30M; Long-term investments: $135.02M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$1.46B; Total debt: $2.18B; Cash and investments: $726.30M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-09; EPS estimate: $0.21 per share; Revenue estimate: $639.97M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
Data provided for informational purposes only.